Myovant Sciences Receives Positive CHMP Opinion for ORGOVYX^® (relugolix) for the Treatment of Advanced Prostate Cancer

Myovant Sciences announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending the approval of ORGOVYX® for the treatment of adult patients with advanced hormone-sensitive prostate cancer.